M. Pavel

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours

Atsuko Kasajima, M. Pavel, Silvia Darb‐Esfahani et al. · Endocrine Related Cancer · 2010 · 103 citations · Full text

Medicine, Oncology, Pharmacology +17

Everolimus (Eve) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (Pnet): Final Overall Survival (Os) Results of a Randomized, Double-Blind, Placebo (Pbo)-Controlled, Multicenter Phase III Trial (Radiant-3)

Jingyu Yao, M. Pavel, Catherine Lombard‐Bohas et al. · Annals of Oncology · 2014 · 13 citations

Medicine, Oncology, Radiation Oncology +16

Effect of everolimus on the pharmacokinetics of octreotide long‐acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT‐2 trial

M. Pavel, Carlos Becerra, Kai Grosch et al. · Clinical Pharmacology & Therapeutics · 2016 · 11 citations

Medicine, Oncology, Pharmacology +14